Chronic obstructive pulmonary disease, bronchiectasis, asthma
Conditions
Interventions
Trial group:Newly developed intervention + current clinical treatment regimen (including bacterial lysate capsules 7.0mg per capsule, once daily orally, for 10 consecutive days per month, continuous u
azithromycin 0.25g per tablet, once daily orally, 3-5 days
COPD dual/triple therapy
bronchiectasis routine treatment
asthma control inadequate treatment regimen, etc.)
Control group:Current clinical treatment regimen (including COPD dual/triple therapy
Sponsors
Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnostic criteria for COPD in accordance with the GOLD guidelines; 2. Confirmed bronchiectasis by high-resolution CT (HRCT); 3. Diagnostic criteria for asthma in accordance with the GINA guidelines.
Exclusion criteria
Exclusion criteria: 1. Severe dysfunction of vital organs such as the heart, liver, and kidneys; 2. Long-term oral administration or recent (within 4 weeks) use of glucocorticoids or immunosuppressants; 3. Presence of cognitive impairment or mental illness, unable to cooperate with the study or treatment; 4. Contraindications or allergy history to the study medication or intervention measures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in alpha diversity (Shannon index) of bronchoalveolar lavage fluid/sputum microbiota from baseline after intervention; | — |
Secondary
| Measure | Time frame |
|---|---|
| Alterations in microbiome composition;Improvement in pulmonary function;Patient-reported outcomes;Rate of acute exacerbations; | — |
Countries
China
Contacts
Public ContactXue Xinying
Xuanwu Hospital, Capital Medical University
Outcome results
None listed